PT2030
Designation of the project | spinUP
Project Code | ALT2030-FSE+-00482200
Main goal | Increase of highly qualified human resources
Region of activity | Lisbon
Beneficiary | biosurfit S.A.
Start date | 01-01-2025
End Date | 30-06-2027
Total eligible value | 449 583,76€
EU Financing | 449 583,76€.
Project summary
Biosurfit, as Portuguese company specialising in in vitro diagnostic (IVD) tests for point-of-care, has a strong profile aligned with the objectives of ALT2030-2023-12. Known for its spinit® system, which enables rapid blood analysis, the company supports fast diagnostic and treatment decisions. biosurfit also offers contract development and manufacturing services, fostering innovation and partnerships.
In 2015, biosurfit secured €12 million from the European Investment Bank under InnovFin, supporting the development and global expansion of spinit®. Its commitment to innovation, regional competitiveness, and qualified job creation aligns with Alentejo's regional strategy, enhancing healthcare solutions for the community. This positions Biosurfit as a strong candidate for ALT2030-2023-12, adding value to the region's strategic goals..
Strategic goals
- Innovation in Healthcare: Develop and commercialise a new spinit® test for the detection of Lipoprotein(a), contributing to advancements in cardiovascular diagnostics.
- Market Expansion: Strengthen biosurfit’s presence in the European medical diagnostics market through targeted marketing strategies and an optimised operations chain.
- Team Growth: Recruit skilled professionals to enhance R&D, operational processes, and marketing, supporting the company’s sustainable growth.
- Regional Contribution: Align project activities with Alentejo’s RIS3 priorities, promoting smart specialisation and economic development in the region.